{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T16:07:24Z","timestamp":1790870844732,"version":"4.1.0"},"reference-count":59,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2011,5,1]],"date-time":"2011-05-01T00:00:00Z","timestamp":1304208000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,5,1]],"date-time":"2011-05-01T00:00:00Z","timestamp":1304208000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2011,5]]},"DOI":"10.4158\/ep10106.ra","type":"journal-article","created":{"date-parts":[[2011,3,31]],"date-time":"2011-03-31T22:18:43Z","timestamp":1301609923000},"page":"430-440","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Mechanistic and Clinical Aspects of Renin-Angiotensin-Aldosterone System Blockade in the Prevention of Diabetes Mellitus and Cardiovascular Disease"],"prefix":"10.1016","volume":"17","author":[{"given":"Kenneth S.","family":"Hershon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.4158\/EP10106.RA_bb0010","doi-asserted-by":"crossref","first-page":"596","DOI":"10.2337\/dc08-9017","article-title":"Economic costs of diabetes in the U.S. in 2007 (Erratum in","volume":"31","author":"American Diabetes Association","year":"2008","journal-title":"Diabetes Care."},{"issue":"Suppl 1","key":"10.4158\/EP10106.RA_bb0015","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.2337\/dc09-S013","article-title":"Standards of medical care in diabetes-2009.","volume":"32","author":"American Diabetes Association","year":"2009","journal-title":"Diabetes Care."},{"key":"10.4158\/EP10106.RA_bb0020","unstructured":"Centers for Disease Control and Prevention. Estimates of diagnosed diabetes now available for all U.S. counties. 2008. Available at: http:\/\/www.cdc.gov\/media\/pressrel\/2008\/r080624.htm"},{"key":"10.4158\/EP10106.RA_bb0025","first-page":"1","article-title":"Diagnosis, prognosis, and treatment of impaired glucose tolerance and impaired fasting glucose","volume":"128","author":"Santaguida","year":"2005","journal-title":"Evid Rep Technol Assess (Summary)"},{"key":"10.4158\/EP10106.RA_bb0030","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.2165\/00003495-200464220-00004","article-title":"Prevention of type 2 diabetes mellitus through inhibition of the renin-angiotensin system","volume":"64","author":"Scheen","year":"2004","journal-title":"Drugs"},{"key":"10.4158\/EP10106.RA_bb0035","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/j.1559-4564.2006.05460.x","article-title":"Involvement of the pancreatic renin-angiotensin system in insulin resistance and the metabolic syndrome","volume":"1","author":"Leung","year":"2006","journal-title":"J Cardiometab Syndr"},{"key":"10.4158\/EP10106.RA_bb0040","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1152\/physrev.1996.76.2.425","article-title":"Paracrine regulation of the renal microcirculation","volume":"76","author":"Navar","year":"1996","journal-title":"Physiol Rev"},{"key":"10.4158\/EP10106.RA_bb0045","first-page":"F141","article-title":"Renal actions of angiotensin-(1-7): In vivo and in vitro studies","volume":"270","author":"Handa","year":"1996","journal-title":"Am J Physiol"},{"key":"10.4158\/EP10106.RA_bb0050","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1161\/01.HYP.34.4.950","article-title":"State-of-the-Art lecture. Antiproliferative actions of angiotensin-(1-7) in vascular smooth muscle","volume":"34","author":"Tallant","year":"1999","journal-title":"Hypertension"},{"key":"10.4158\/EP10106.RA_bb0055","doi-asserted-by":"crossref","first-page":"E353","DOI":"10.1152\/ajpendo.00402.2004","article-title":"Abrogation of oxidative stress improves insulin sensitivity in the Ren-2 rat model of tissue angiotensin II overexpression","volume":"288","author":"Blendea","year":"2005","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.4158\/EP10106.RA_bb0060","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.tem.2005.02.003","article-title":"The renin-angiotensin-aldosterone system, glucose metabolism and diabetes","volume":"16","author":"Giacchetti","year":"2005","journal-title":"Trends Endocrinol Metab"},{"key":"10.4158\/EP10106.RA_bb0065","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.amjhyper.2004.07.001","article-title":"Of the renin-angiotensin system and reactive oxygen species type 2 diabetes and angiotensin II inhibition","volume":"18","author":"Leiter","year":"2005","journal-title":"Am J Hypertens"},{"key":"10.4158\/EP10106.RA_bb0070","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1089\/ars.2007.1629","article-title":"Oxidative stress, glucose metabolism, and the prevention of type 2 diabetes: Pathophysiological insights","volume":"9","author":"Shah","year":"2007","journal-title":"Antioxid Redox Signal"},{"key":"10.4158\/EP10106.RA_bb0075","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1161\/01.HYP.0000125142.41703.64","article-title":"Angiotensin II type-1 receptor blocker valsartan enhances insulin sensitivity in skeletal muscles of diabetic mice","volume":"43","author":"Shiuchi","year":"2004","journal-title":"Hypertension"},{"key":"10.4158\/EP10106.RA_bb0080","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.mce.2008.12.011","article-title":"Angiotensin II and the development of insulin resistance: Implications for diabetes","volume":"302","author":"Olivares-Reyes","year":"2009","journal-title":"Mol Cell Endocrinol"},{"key":"10.4158\/EP10106.RA_bb0085","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1161\/01.HYP.35.6.1270","article-title":"Physiology and pathophysiology of the adipose tissue renin-angiotensin system","volume":"35","author":"Engeli","year":"2000","journal-title":"Hypertension"},{"key":"10.4158\/EP10106.RA_bb0090","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.2337\/diabetes.51.6.1699","article-title":"Mature adipocytes inhibit in vitro differentiation of human preadipocytes via angiotensin type 1 receptors","volume":"51","author":"Janke","year":"2002","journal-title":"Diabetes"},{"key":"10.4158\/EP10106.RA_bb0095","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1038\/ki.2008.391","article-title":"Renin-angiotensin system blockade and diabetes: Moving the adipose organ from the periphery to the center","volume":"74","author":"Lenz","year":"2008","journal-title":"Kidney Int"},{"key":"10.4158\/EP10106.RA_bb0100","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1210\/endo.142.1.7883","article-title":"Angiotensin II as a trophic factor of white adipose tissue: Stimulation of adipose cell formation","volume":"142","author":"Saint-Marc","year":"2001","journal-title":"Endocrinology"},{"key":"10.4158\/EP10106.RA_bb0105","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1097\/00004872-200205000-00032","article-title":"Hormonal regulation of the human adipose-tissue renin-angiotensin system: Relationship to obesity and hypertension","volume":"20","author":"Gorzelniak","year":"2002","journal-title":"J Hypertens"},{"key":"10.4158\/EP10106.RA_bb0110","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/j.1440-1797.2007.00764.x","article-title":"Effect of antihypertensive agents on plasma adiponectin levels in hypertensive patients with metabolic syndrome","volume":"12","author":"Yilmaz","year":"2007","journal-title":"Nephrology (Carlton)"},{"key":"10.4158\/EP10106.RA_bb0115","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1161\/01.HYP.21.2.136","article-title":"The vasodilator action of insulin. Implications for the insulin hypothesis of hypertension [Erratum in: Hypertension. 1993;21:745]","volume":"21","author":"Anderson","year":"1993","journal-title":"Hypertension"},{"key":"10.4158\/EP10106.RA_bb0120","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1161\/HYPERTENSIONAHA.107.089284","article-title":"NADPH oxidase contributes to vascular inflammation, insulin resistance, and remodeling in the transgenic (mRen2) rat","volume":"50","author":"Wei","year":"2007","journal-title":"Hypertension"},{"key":"10.4158\/EP10106.RA_bb0125","doi-asserted-by":"crossref","first-page":"E345","DOI":"10.1152\/ajpendo.00456.2007","article-title":"Angiotensin II-induced skeletal muscle insulin resistance mediated by NF-kB activation via NADPH oxidase","volume":"294","author":"Wei","year":"2008","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.4158\/EP10106.RA_bb0130","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.2169\/internalmedicine.46.7173","article-title":"Comparative effects of telmisartan and valsartan on insulin resistance in hypertensive patients with metabolic syndrome","volume":"46","author":"Ichikawa","year":"2007","journal-title":"Intern Med"},{"key":"10.4158\/EP10106.RA_bb0135","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1097\/01.hjh.0000188734.98463.82","article-title":"Hemodynamic and metabolic responses to valsartan and atenolol in obese hypertensive patients","volume":"23","author":"Jordan","year":"2005","journal-title":"J Hypertens"},{"key":"10.4158\/EP10106.RA_bb0140","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1097\/00004872-200308000-00022","article-title":"Metabolic outcome during 1 year in newly detected hypertensives: Results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study)","volume":"21","author":"Lindholm","year":"2003","journal-title":"J Hypertens"},{"key":"10.4158\/EP10106.RA_bb0145","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/sj.jhh.1000434","article-title":"Losartan mediated improvement in insulin action is mainly due to an increase in non-oxidative glucose metabolism and blood flow in insulin-resistant hypertensive patients","volume":"11","author":"Paolisso","year":"1997","journal-title":"J Hum Hypertens"},{"key":"10.4158\/EP10106.RA_bb0150","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1177\/147323000203000103","article-title":"The effects of valsartan on insulin sensitivity in patients with primary hypertension","volume":"30","author":"Top","year":"2002","journal-title":"J Int Med Res"},{"key":"10.4158\/EP10106.RA_bb0155","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1113\/jphysiol.2006.126193","article-title":"The physiology of a local renin-angiotensin system in the pancreas","volume":"580","author":"Leung","year":"2007","journal-title":"J Physiol"},{"key":"10.4158\/EP10106.RA_bb0160","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1124\/jpet.108.142703","volume":"327","author":"Cheng","year":"2008","journal-title":"J Pharmacol Exp Ther"},{"key":"10.4158\/EP10106.RA_bb0165","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1530\/eje.1.02086","article-title":"The direct effects of the angiotensin-converting enzyme inhibitors, zofenoprilat and enalaprilat, on isolated human pancreatic islets","volume":"154","author":"Lupi","year":"2006","journal-title":"Eur J Endocrinol"},{"key":"10.4158\/EP10106.RA_bb0170","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.bbrc.2005.05.065","article-title":"Increased expression of NAD(P)H oxidase in islets of animal models of type 2 diabetes and its improvement by an AT1 receptor antagonist","volume":"332","author":"Nakayama","year":"2005","journal-title":"Biochem Biophys Res Commun"},{"key":"10.4158\/EP10106.RA_bb0175","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1097\/HJH.0b013e328332bcf0","article-title":"Improving vascular function in hypertension: Potential benefits of combination therapy with amlodipine and renin-angiotensin-aldosterone system blockers","volume":"28","author":"Siragy","year":"2010","journal-title":"J Hypertens"},{"key":"10.4158\/EP10106.RA_bb0180","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1161\/CIRCULATIONAHA.106.179294","article-title":"Primary prevention of cardiovascular diseases in people with diabetes mellitus: A scientific statement from the American Heart Association and the American Diabetes Association","volume":"115","author":"Buse","year":"2007","journal-title":"Circulation"},{"key":"10.4158\/EP10106.RA_bb0185","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1001\/jama.286.15.1882","article-title":"HOPE Study Investigators. Ramipril and the development of diabetes","volume":"286","author":"Yusuf","year":"2001","journal-title":"JAMA"},{"key":"10.4158\/EP10106.RA_bb0190","first-page":"145","article-title":"Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators [Errata in: N Engl J Med. 2000;342:748 and N Engl J Med. 2000;342:1376]","volume":"342","author":"Yusuf","year":"2000","journal-title":"N Engl J Med"},{"key":"10.4158\/EP10106.RA_bb0195","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1056\/NEJMoa065061","article-title":"Effect of ramipril on the incidence of diabetes.","volume":"355","author":"DREAM Trial Investigators","year":"2006","journal-title":"N Engl J Med."},{"key":"10.4158\/EP10106.RA_bb0200","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1161\/01.CIR.0000054611.89228.92","article-title":"Enalapril reduces the incidence of diabetes in patients with chronic heart failure: Insight from the Studies of Left Ventricular Dysfunction (SOLVD)","volume":"107","author":"Vermes","year":"2003","journal-title":"Circulation"},{"key":"10.4158\/EP10106.RA_bb0205","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S0140-6736(98)05012-0","article-title":"Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: The Captopril Prevention Project (CAPPP) randomised trial","volume":"353","author":"Hansson","year":"1999","journal-title":"Lancet"},{"key":"10.4158\/EP10106.RA_bb0210","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1001\/jama.288.23.2981","volume":"288","author":"ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group","year":"2002","journal-title":"JAMA."},{"key":"10.4158\/EP10106.RA_bb0215","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1097\/00004872-200209000-00035","article-title":"Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study","volume":"20","author":"Lindholm","year":"2002","journal-title":"J Hypertens"},{"key":"10.4158\/EP10106.RA_bb0220","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1161\/CIRCULATIONAHA.104.528166","article-title":"Candesartan in Heart Failure-Assessment of Reduction in Mortality and Morbidity Program Investigators. Effects of candesartan on the development of a new diagnosis of diabetes mellitus in patients with heart failure","volume":"112","author":"Yusuf","year":"2005","journal-title":"Circulation"},{"key":"10.4158\/EP10106.RA_bb0225","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1097\/00004872-200305000-00011","article-title":"The Study on Cognition and Prognosis in the Elderly (SCOPE): Principal results of a randomized double-blind intervention trial","volume":"21","author":"Lithell","year":"2003","journal-title":"J Hypertens"},{"key":"10.4158\/EP10106.RA_bb0230","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1097\/01.hjh.0000234122.55895.5b","article-title":"VALUE Trial Investigators. Effects of valsartan compared to amlodipine on preventing type 2 diabetes in high-risk hypertensive patients: Tthe VALUE trial","volume":"24","author":"Kjeldsen","year":"2006","journal-title":"J Hypertens"},{"key":"10.4158\/EP10106.RA_bb0235","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1056\/NEJMoa1001121","article-title":"Effect of valsartan on the incidence of diabetes and cardiovascular events [Erratum in:","volume":"362","author":"The NAVIGATOR Study Group","year":"2010","journal-title":"N Engl J Med."},{"key":"10.4158\/EP10106.RA_bb0240","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S0140-6736(02)08089-3","article-title":"Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint Reduction in Hypertension Study (LIFE): A randomised trial against atenolol","volume":"359","author":"Dahl\u00f6f","year":"2002","journal-title":"Lancet"},{"key":"10.4158\/EP10106.RA_bb0245","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/S0140-6736(03)14974-4","volume":"362","author":"Fox","year":"2003","journal-title":"Lancet"},{"key":"10.4158\/EP10106.RA_bb0250","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1056\/NEJMoa021716","article-title":"A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly","volume":"348","author":"Wing","year":"2003","journal-title":"N Engl J Med"},{"key":"10.4158\/EP10106.RA_bb0255","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.ahj.2008.05.017","article-title":"Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: Rationale and design of the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR)","volume":"156","author":"Califf","year":"2008","journal-title":"Trial. Am Heart J"},{"key":"10.4158\/EP10106.RA_bb0260","series-title":"Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus","author":"World Health Organization","year":"1999"},{"key":"10.4158\/EP10106.RA_bb0265","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1172\/JCI7231","article-title":"The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus","volume":"104","author":"Weyer","year":"1999","journal-title":"J Clin Invest"},{"key":"10.4158\/EP10106.RA_bb0270","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1056\/NEJMoa010713","article-title":"Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure","volume":"345","author":"Cohn","year":"2001","journal-title":"N Engl J Med"},{"key":"10.4158\/EP10106.RA_bb0275","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1056\/NEJMoa032292","article-title":"Valsartan in Acute Myocardial Infarction Trial Investigators. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both","volume":"349","author":"Pfeffer","year":"2003","journal-title":"N Engl J Med"},{"key":"10.4158\/EP10106.RA_bb0280","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1016\/S0140-6736(02)08905-5","article-title":"STOP-NIDDM Trail Research Group. Acarbose for prevention of type 2 diabetes mellitus: The STOP-NIDDM randomised trial","volume":"359","author":"Chiasson","year":"2002","journal-title":"Lancet"},{"key":"10.4158\/EP10106.RA_bb0285","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.2174\/138161207780618768","article-title":"Role of renin angiotensin system inhibitors in cardiovascular and renal protection: A lesson from clinical trials","volume":"13","author":"Stojiljkovic","year":"2007","journal-title":"Curr Pharm Des"},{"key":"10.4158\/EP10106.RA_bb0290","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s12325-010-0028-3","article-title":"Comparing angiotensin II receptor blockers on benefits beyond blood pressure","volume":"27","author":"Siragy","year":"2010","journal-title":"Adv Ther"},{"key":"10.4158\/EP10106.RA_bb0295","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/j.1751-7141.2008.00004.x","article-title":"Use of angiotensin-converting enzyme inhibitor\/angiotensin receptor blocker therapy to reduce cardiovascular events in high-risk patients: Part 2","volume":"11","author":"Bommer","year":"2008","journal-title":"Prev Cardiol"},{"key":"10.4158\/EP10106.RA_bb0300","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1111\/j.1751-7141.2008.08435.x","article-title":"Use of angiotensin-converting enzyme inhibitor\/angiotensin II receptor blocker therapy to reduce cardiovascular events in high-risk patients: Part 1","volume":"11","author":"Bommer","year":"2008","journal-title":"Prev Cardiol"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X20404239?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X20404239?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/aace.metapress.com\/index\/U901142052056G04.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:53:22Z","timestamp":1761515602000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X20404239"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,5]]},"references-count":59,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,5]]}},"alternative-id":["S1530891X20404239"],"URL":"https:\/\/doi.org\/10.4158\/ep10106.ra","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2011,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mechanistic and Clinical Aspects of Renin-Angiotensin-Aldosterone System Blockade in the Prevention of Diabetes Mellitus and Cardiovascular Disease","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.4158\/EP10106.RA","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}